List of Excipients in Branded Drug DOBUTAMINE HYDROCHLORIDE IN DEXTROSE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Baxter Healthcare Corporation	DOBUTAMINE HYDROCHLORIDE IN DEXTROSE	dobutamine hydrochloride	0338-1073	DEXTROSE MONOHYDRATE
Baxter Healthcare Corporation	DOBUTAMINE HYDROCHLORIDE IN DEXTROSE	dobutamine hydrochloride	0338-1073	HYDROCHLORIC ACID
Baxter Healthcare Corporation	DOBUTAMINE HYDROCHLORIDE IN DEXTROSE	dobutamine hydrochloride	0338-1073	SODIUM BISULFITE
Baxter Healthcare Corporation	DOBUTAMINE HYDROCHLORIDE IN DEXTROSE	dobutamine hydrochloride	0338-1073	SODIUM HYDROXIDE
Baxter Healthcare Corporation	DOBUTAMINE HYDROCHLORIDE IN DEXTROSE	dobutamine hydrochloride	0338-1073	WATER
A-S Medication Solutions	DOBUTAMINE HYDROCHLORIDE IN DEXTROSE	dobutamine hydrochloride	50090-4562	DEXTROSE MONOHYDRATE
A-S Medication Solutions	DOBUTAMINE HYDROCHLORIDE IN DEXTROSE	dobutamine hydrochloride	50090-4562	HYDROCHLORIC ACID

Dobutamine Hydrochloride in Dextrose: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 15, 2026

Dobutamine hydrochloride in dextrose is a mature sterile injectable with low active-ingredient patent risk and limited formulation complexity. Commercial value depends on supply reliability, ready-to-administer presentation, container performance, stability, and hospital purchasing economics rather than exclusivity. The principal excipient is dextrose, typically supplied as a 5% solution in water for injection. Product developers can compete through premixed bags, concentration options, low-sorption containers, longer validated shelf life, and dependable critical-care supply.

What is dobutamine hydrochloride in dextrose used for?

Dobutamine is a synthetic catecholamine indicated for short-term inotropic support in adults with cardiac decompensation caused by depressed contractility. It increases myocardial contractility primarily through beta-1 adrenergic stimulation and is administered by continuous intravenous infusion under clinical monitoring.[1]

Dobutamine hydrochloride in dextrose is a ready-to-use infusion product. It avoids bedside dilution of a concentrated vial and can reduce preparation steps in intensive-care units, cardiac-care units, emergency departments, and operating rooms.

Typical commercial presentations include:

Product characteristic	Commercial relevance
Active ingredient	Dobutamine hydrochloride
Therapeutic category	Intravenous inotrope
Dosage form	Sterile solution for infusion
Primary vehicle	5% dextrose in water
Administration	Continuous intravenous infusion
Typical strengths	Concentrations vary by manufacturer and presentation
Container types	Flexible bags, premixed containers, or pharmacy bulk formats
Storage requirement	Controlled room-temperature or labeled refrigerated/room-temperature conditions, depending on product
Key quality risks	Oxidation, particulate formation, container interaction, potency loss, and microbial contamination

Dobutamine is generally administered through an infusion pump. The prescribing information requires dilution and controlled administration for concentrated products. Premixed dextrose presentations address this operational requirement by placing the drug at a labeled infusion concentration.

Which excipients are used in dobutamine hydrochloride in dextrose?

The excipient strategy is intentionally narrow. Dextrose provides the infusion vehicle and osmotic contribution, while water for injection is the solvent. Some concentrated dobutamine injection products contain a sulfite antioxidant, but the exact excipient profile depends on the manufacturer and dosage form.[1,2]

Dextrose

Dextrose is used as a 5% aqueous infusion vehicle in many premixed dobutamine products. Its advantages include:

• Established parenteral use
• Broad hospital familiarity
• Compatibility with continuous intravenous administration
• Established compendial and regulatory standards
• Commercial availability in large-volume parenteral manufacturing

Its limitations include glucose exposure, osmolarity considerations, and incompatibility for some patient populations. A dextrose-based product may be less attractive than a sodium-chloride-based product for patients in whom glucose administration is undesirable.

Water for injection

Water for injection is the solvent and must comply with applicable compendial requirements for chemical quality, endotoxins, and sterility controls. It is not an optional formulation variable for a conventional aqueous injectable.

Sulfite antioxidants

Dobutamine is chemically susceptible to oxidation. Some dobutamine injection labels identify sodium metabisulfite or another sulfite-containing antioxidant in concentrated formulations.[1] A sulfite antioxidant can improve chemical stability but introduces a labeling issue because sulfites may cause allergic-type reactions, including severe reactions in susceptible individuals.

A premixed formulation can pursue either of two strategies:

1. Use a validated antioxidant system where necessary.
2. Use formulation pH control, oxygen management, low-headspace filling, and oxygen-barrier packaging to minimize or eliminate added sulfite.

The second strategy may create a marketable differentiation, but it requires comparative stability data, container-closure integrity data, and a clear regulatory justification.

pH adjustment

Dobutamine solutions are typically formulated within an acidic pH range to support chemical stability. Hydrochloride salt formation improves aqueous solubility, while pH selection affects degradation, color development, and container compatibility.

pH adjustment agents may be present in the formulation, although they are not always highlighted in commercial marketing materials. The target pH must be controlled tightly because changes can affect stability and infusion tolerability.

What formulation attributes determine commercial performance?

The strongest commercial opportunities are linked to product handling and shelf life rather than new pharmacology.

Oxidative stability

Dobutamine can undergo oxidation, with potential color change and potency loss. A robust formulation program should evaluate:

• Oxygen concentration in the filled container
• Headspace volume and composition
• Light exposure
• Temperature excursions
• pH drift
• Degradation products
• Antioxidant concentration, if used
• Container-closure integrity

The product should be evaluated under accelerated and long-term conditions using stability-indicating analytical methods. Color change is commercially important because visible discoloration can trigger hospital rejection even when assay results remain within specification.

Container compatibility

Flexible infusion bags may contain multilayer polymer films with different oxygen permeability and drug-sorption characteristics. Product developers should assess:

• Drug adsorption or absorption into the polymer
• Extractables and leachables
• Oxygen transmission
• Moisture transmission
• Port integrity
• Label adhesion
• Compatibility with overwraps
• Performance during refrigerated storage and transport

A low-sorption, oxygen-barrier bag can support a differentiation strategy if it produces longer shelf life or better stability than existing products.

Concentration selection

Concentration is a practical differentiator. Hospitals may prefer standard concentrations that reduce pump programming errors and simplify nursing protocols. Higher concentrations can reduce fluid volume for patients with fluid restrictions, while lower concentrations can support peripheral administration protocols where clinically appropriate.

Potential presentations include:

Presentation strategy	Commercial rationale
Standard adult concentration	Aligns with hospital protocols and purchasing contracts
High-concentration bag	Reduces fluid volume in critical-care patients
Small-volume ready-to-use container	Supports transport, emergency use, and lower waste
Pharmacy bulk package	Supports centralized hospital preparation
Multiple dextrose concentrations	Addresses glucose-management preferences
Sodium-chloride alternative	Expands use where dextrose is undesirable

The dosage concentration must remain consistent with approved labeling and institutional medication-safety requirements. A concentration portfolio can increase manufacturing complexity and inventory costs, so the commercial benefit must be demonstrated through purchasing data and hospital protocol alignment.

What patents protect dobutamine hydrochloride in dextrose?

Dobutamine is an old small-molecule active ingredient, and the core compound patent estate is not an effective barrier to entry. The active ingredient was developed decades ago, and commercially relevant market protection is generally based on regulatory approval, manufacturing capability, and supply contracts rather than current composition-of-matter exclusivity.

The relevant intellectual-property categories are:

IP category	Likely strategic value
Dobutamine compound patents	Expired or commercially irrelevant for current entry
Basic aqueous formulation patents	Limited opportunity because the formulation is conventional
Premixed bag configuration	Potentially protectable only where a specific technical solution is novel
Oxygen-control packaging	Potential value if linked to unexpected stability or shelf-life results
Manufacturing process	Possible protection for specialized filling, deoxygenation, or sterilization methods
Container-closure system	Potential patent value, but often more important as know-how
Method-of-use patents	Limited value for a mature, established inotrope
Trade secrets	Important for process controls, filling parameters, and stability management

A conventional dobutamine hydrochloride solution in 5% dextrose is unlikely to support a strong broad formulation patent. Patent value would require a specific technical feature, such as a non-obvious antioxidant system, a defined oxygen threshold, a novel container film, an unusual concentration range, or a demonstrated stability improvement.

What is the Orange Book status of dobutamine hydrochloride in dextrose?

Dobutamine products are generally regulated as prescription sterile injectable drugs. The FDA Orange Book records approved drug products and, where applicable, patent and exclusivity information. Mature injectable products may have limited or no active listed patent protection, depending on the specific reference product and product presentation.[3]

For a generic applicant, the principal regulatory route is usually an abbreviated new drug application when the proposed product can demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy applicable injectable-drug requirements. Because dobutamine is administered intravenously, the development package focuses heavily on:

• Active and inactive ingredient sameness or justified differences
• Strength and dosage form
• Sterility and endotoxin control
• Pharmaceutical equivalence
• Product quality and stability
• Container-closure compatibility
• Labeling alignment
• Manufacturing-process validation

A 505(b)(2) pathway may be relevant for a product with a materially different formulation, concentration, container, or dosing presentation that cannot qualify as a conventional ANDA product. The commercial benefit of that route must justify the additional clinical, regulatory, and launch complexity.

When does dobutamine hydrochloride in dextrose lose exclusivity?

The practical exclusivity period has already expired for the underlying dobutamine molecule. The commercial market is therefore open to approved generic and branded-generic suppliers, subject to manufacturing compliance, product availability, and regulatory approval.

The key distinction is between:

• Molecular exclusivity: expired for this mature small molecule.
• Regulatory exclusivity: generally not the principal barrier for conventional dobutamine injectable products.
• Patent exclusivity: formulation or device claims could exist for specific products, but broad protection is unlikely for a conventional dextrose solution.
• Contractual access: hospital group-purchasing contracts can create temporary commercial advantages without creating legal exclusivity.

Launch timing is controlled mainly by development, FDA review, manufacturing readiness, and procurement cycles. A new entrant can receive approval and still face delayed market penetration if it lacks validated sterile capacity or cannot secure hospital contracts.

What Paragraph IV challenges and litigation affect dobutamine?

Paragraph IV litigation risk appears structurally low for a conventional dobutamine hydrochloride in dextrose product because the active ingredient is mature and the likely formulation is technically straightforward. A Paragraph IV certification could arise if an ANDA applicant identifies a listed patent covering a specific reference product, container, formulation, or method of use.

Potential disputes would likely concern:

• Whether a formulation claim covers the proposed excipient system
• Whether a container or packaging claim is infringed
• Whether a stability or manufacturing claim is valid
• Whether the applicant’s product is materially different from the patented product
• Whether the patent is invalid for anticipation or obviousness

There is no biosimilar pathway for dobutamine because it is a chemically synthesized small molecule, not a biologic. The relevant competitive threat is generic entry, not biosimilar substitution.

Which companies compete in the dobutamine injectable market?

Competition typically includes large generic injectable manufacturers, hospital-supply companies, and contract manufacturing organizations. Relevant commercial participants may include Pfizer’s Hospira business, Hikma, Fresenius Kabi, Sagent, and other FDA-approved sterile-injectable suppliers, depending on current product availability and national contracts.[2,4]

The competitive landscape is shaped by:

• FDA-approved manufacturing sites
• Shortage history
• Availability of ready-to-use presentations
• Bag and vial formats
• Hospital group-purchasing organization contracts
• Manufacturing redundancy
• Ability to maintain supply during recalls or plant outages
• Pricing under generic injectable tenders

Hospital buyers often value supply continuity more than modest unit-price differences for critical-care medicines. A supplier with multiple sterile facilities or qualified alternate sources can obtain a commercial advantage.

What commercial opportunities exist for excipient innovation?

The best opportunities are incremental and operational.

Sulfite-free or reduced-sulfite formulations

A sulfite-free formulation could address institutions that prefer to minimize sulfite exposure. The product would need to demonstrate adequate stability through oxygen control, packaging selection, pH optimization, and validated manufacturing controls.

Low-volume, high-concentration products

High-concentration ready-to-use bags can reduce fluid burden. The target market includes cardiac intensive-care units and patients receiving multiple continuous infusions.

Extended shelf life

A longer labeled shelf life can reduce inventory write-offs and improve emergency stock management. The commercial case is strongest where the product remains stable through normal hospital storage without special handling.

Improved container systems

A container with lower oxygen permeability, better port design, or enhanced transport durability can reduce waste and administration failures. These attributes may be protectable through patents, but trade-secret process control and procurement specifications may provide more practical value.

Dextrose-free alternatives

A sodium-chloride presentation can expand the portfolio for patients requiring avoidance of dextrose. It also gives hospitals an alternative when glucose load, hyperglycemia management, or compatibility concerns limit use of dextrose.

Ready-to-administer emergency formats

Smaller bags or syringes can target emergency departments, transport teams, operating rooms, and cardiac catheterization settings. The opportunity depends on compatibility with automated dispensing systems and institutional infusion protocols.

How strong is the patent estate for dobutamine hydrochloride in dextrose?

The patent estate is weak for the conventional formulation and potentially moderate for a differentiated delivery system.

Area	Assessment
Active ingredient	Low patent barrier
Conventional dextrose solution	Low patent barrier
Premixed infusion format	Low to moderate, depending on technical claims
Oxygen-controlled package	Moderate if supported by unexpected stability data
Novel concentration range	Moderate only if clinically and technically justified
Sulfite-free formulation	Moderate if stability improvement is non-obvious
Manufacturing process	Moderate as trade secret; patent strength depends on claim specificity
Hospital procurement position	Commercially important but not patent-based

A new applicant should prioritize freedom-to-operate review around packaging, sterilization, filling, and stability claims rather than the dobutamine molecule itself.

What generic launch risks exist for dobutamine hydrochloride in dextrose?

The principal launch risks are operational:

1. Sterile manufacturing failure or FDA inspection findings.
2. Visible discoloration or stability-related product complaints.
3. Container interaction or extractables and leachables problems.
4. Inability to match the reference product’s concentration and labeling.
5. Limited access to hospital purchasing contracts.
6. Product shortages caused by dependence on a single manufacturing site.
7. Low unit prices that do not support adequate manufacturing redundancy.
8. Inventory losses caused by short shelf life.
9. Competition from vial products that hospitals dilute internally.
10. Clinical reluctance to adopt a nonstandard concentration.

The highest-value commercial position is a dependable, ready-to-use product with a familiar concentration, strong stability profile, and multiple manufacturing or supply sources.

What licensing opportunities exist?

Licensing opportunities are more likely to involve technology and supply than core drug rights. Potential transactions include:

• Co-development of a ready-to-use bag
• Contract manufacturing using an established sterile facility
• Licensing of an oxygen-barrier container system
• Regional commercialization rights
• Hospital-contract manufacturing arrangements
• Private-label supply for generic injectable distributors
• Acquisition of an approved ANDA or sterile injectable portfolio

A formulation patent license is less likely to be essential unless the product uses a proprietary container or antioxidant system. The most practical transaction structure may combine manufacturing capacity, regulatory ownership, and commercial distribution.

What is the revenue exposure and market outlook?

Dobutamine is a hospital product with concentrated use in critical-care settings. Revenue is constrained by generic pricing and intermittent demand, but supply disruptions can materially increase the value of a reliable supplier. Market opportunity should be assessed through:

• Annual hospital unit volume
• Average selling price by presentation
• Contract versus spot-market sales
• Shortage frequency
• Number of qualified suppliers
• Share of premixed versus vial presentations
• ICU and cardiac-care utilization
• Cost of sterile manufacturing capacity

A portfolio approach is stronger than a single-product launch. Dobutamine can be paired with other critical-care infusions, such as norepinephrine, epinephrine, milrinone, or dopamine, using common hospital distribution channels. The commercial logic is improved when the supplier can offer a broader ready-to-administer injectable range.

Key Takeaways

• Dobutamine hydrochloride in dextrose is a mature sterile injectable with minimal active-ingredient exclusivity risk.
• Dextrose 5% in water is the principal vehicle in common premixed presentations.
• Oxidative stability, pH control, sulfite use, oxygen management, and container selection drive formulation performance.
• The strongest opportunities are ready-to-use bags, high-concentration formats, smaller containers, extended shelf life, and sulfite-free or reduced-sulfite products.
• Patent protection for a conventional dobutamine-in-dextrose solution is likely weak; differentiated packaging and stability technologies offer greater IP potential.
• Generic entry risk is high, while biosimilar risk is not applicable.
• Commercial success depends on sterile manufacturing reliability, hospital contracts, product availability, and supply-chain redundancy.
• A broader critical-care injectable portfolio can improve the economics of market entry.

FAQs

Can dobutamine hydrochloride in dextrose be reformulated with sodium chloride?

Yes. A sodium-chloride vehicle can support a separate product strategy, but the formulation requires independent stability, compatibility, labeling, and regulatory evaluation.

Is a sulfite-free dobutamine infusion commercially attractive?

Potentially. It may appeal to hospitals seeking to avoid sulfite exposure, provided the manufacturer can achieve adequate shelf life without sulfite protection.

Can a high-concentration dobutamine bag receive patent protection?

Possibly, but concentration alone is usually weak subject matter. Stronger protection would require a specific technical advantage, such as reduced fluid burden combined with unexpected stability, compatibility, or administration benefits.

Does dobutamine require a biosimilar application?

No. Dobutamine is a chemically synthesized small molecule. Generic-drug pathways, including an ANDA where applicable, are the relevant regulatory framework.

What is the most defensible commercial differentiation for a new entrant?

The strongest position is a ready-to-administer product with a familiar concentration, long shelf life, robust container performance, dependable supply, and access to hospital purchasing contracts.

References

1. U.S. Food and Drug Administration. (2023). Dobutamine hydrochloride injection: Prescribing information. FDA/DailyMed.

2. National Library of Medicine. (2024). DailyMed: Dobutamine hydrochloride injection and dobutamine hydrochloride in dextrose injection labeling. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

4. U.S. Food and Drug Administration. (2024). Drug shortages: Current and resolved drug shortages. FDA Drug Shortages Database.

5. United States Pharmacopeia. (2024). General chapters for sterile preparations, injections, packaging, and container-closure integrity. United States Pharmacopeial Convention.

6. U.S. Food and Drug Administration. (2014). Container closure systems for packaging human drugs and biologics: Chemistry, manufacturing, and controls documentation. FDA Guidance for Industry.